Sandra McCearley, MD
Clinical Cardiac Electrophysiology · Jackson, MSNPI 1861590457
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Abbott at 31.0% of the total. Reporting peaked in 2020 at $2,597 and has fallen 79.4% since, to $534 in 2025.
Across 275 payments — averaging $34.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$2K
- Novartis$1K
- Boehringer Ingelheim$517
- Medtronic$484
- Merck$396
- plus $2K from 23 others
Across 27 payments — averaging $3595.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$97K
What the payments were for
- Consulting fees$2,90030%
- Travel & lodging$1,48916%
- Food & beverage$5,13254%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $2,951 |
| Boston Scientific | 6 | $2,320 |
| Novartis | 77 | $1,175 |
| Boehringer Ingelheim | 26 | $517 |
| Medtronic(2 entities) | 13 | $484 |
| Merck | 19 | $396 |
| Amgen | 26 | $359 |
| Johnson & Johnson | 16 | $189 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $166 |
| Inspire Medical Systems, Inc. | 1 | $150 |
| Pfizer | 10 | $142 |
| E.r. Squibb & Sons, L.L.C. | 8 | $127 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| AstraZeneca | 4 | $64 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Irhythm Technologies, Inc. | 2 | $40 |
| Kestra Medical Technology Services, Inc. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Bayer | 1 | $27 |
| Avinger Inc. | 1 | $24 |
| Cardiva Medical, Inc. | 1 | $22 |
| Siemens Medical Solutions USA, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Terumo Medical Corporation | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 2 | $18 |
| Novo Nordisk | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$2,100
- AVEIR$1,367
- Accent Pacemaker$800
- Inspire$150
- Arctic Front$128
- LINQ II$108
How this compares
Too few clinical cardiac electrophysiology providers in Mississippito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,000 | $749,573 |
| XareltoRivaroxaban | 186 | $155,121 |
| EntrestoSacubitril/Valsartan | 91 | $73,414 |
| Dofetilide | 94 | $14,630 |
| Metoprolol Succinate | 501 | $6,342 |
| Flecainide Acetate | 134 | $4,194 |
| Amiodarone Hcl | 254 | $2,209 |
| Propafenone Hcl | 37 | $1,044 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 40 | $849 |
| Carvedilol | 152 | $837 |
| Digoxin | 45 | $766 |
| SotalolSotalol Hcl | 33 | $704 |
| Metoprolol Tartrate | 114 | $600 |
| Atorvastatin Calcium | 41 | $540 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 70 | $415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $749,5731,000 claims |
| Johnson & JohnsonXarelto | $189 | $155,121186 claims |
| NovartisEntresto | $1,175 | $73,41491 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in Mississippion file to place this against a meaningful peer group, so we don't.
Other clinical cardiac electrophysiology in Jackson
- James Hamilton IvJackson$34K
- Jimmy LottJackson$16K
- Douglas WolfeJackson$9K
- Joseph OwenJackson$8K
- John PayneJackson$197
- Karthik Venkatesh PrasadTupelo$86K
- James StoneTupelo$61K
- Elsheikh AbdelrahimTupelo$35K
- Attila RokaMeridian$16K
- Santo BorganelliHattiesburg$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.